Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Imatinib (STI571)

For research use only.

Catalog No.S2475 Synonyms: Gleevec, Glivec, CGP057148B

207 publications

Imatinib (STI571) Chemical Structure

CAS No. 152459-95-5

Imatinib (STI571, CGP057148B, Gleevec) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib (STI571) induces autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Imatinib (STI571) has been cited by 207 publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Imatinib (STI571, CGP057148B, Gleevec) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib (STI571) induces autophagy.
Targets
PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
In vitro

In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LAMA-84 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M162bmlEPTB;MD6wO|MxPCEQvF2= NG\yUolUSU6JRWK=
EM-2 NHWxSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjRZ2E6UUN3ME2wMlA5QDhizszN M1n6WnNCVkeHUh?=
MEG-01 NHrhcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPRTWM2OD1yLkC4PVIyKM7:TR?= M4fpWXNCVkeHUh?=
BV-173 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G0UGlEPTB;MD6xPFc1KM7:TR?= NYrib|Y2W0GQR1XS
K-562 NXO0dIQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomxTWM2OD1yLkKyOFMzKM7:TR?= NFfjNFhUSU6JRWK=
CGTH-W-1 NYLjbHVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvhTWM2OD1yLkO4N|c1KM7:TR?= NInpZXdUSU6JRWK=
ST486 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D6Z2lEPTB;MD62PFU1KM7:TR?= NXLsVos1W0GQR1XS
NCI-H1436 NVv2eIh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Cwe2lEPTB;MD65O|gxOSEQvF2= MX\TRW5ITVJ?
NOS-1 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnTWJhKSzVyPUGuOlU{QDNizszN MYXTRW5ITVJ?
A498 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwNUeyNlMh|ryP M1O1W3NCVkeHUh?=
BE-13 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjMOFdJUUN3ME2yMlYzOTB4IN88US=> NH;TUmNUSU6JRWK=
SUP-T1 NVfScnhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwOEK5NFch|ryP M{nKUnNCVkeHUh?=
NCI-H1770 NWjHTXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTVwNUeyOlIh|ryP MYLTRW5ITVJ?
IMR-5 NGLLcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq0[|ZKSzVyPU[uNlIyPDdizszN NGD2WIJUSU6JRWK=
LB2241-RCC M1P3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonyTWM2OD16LkC3N|g1KM7:TR?= NXjDRXp6W0GQR1XS
TGBC24TKB NVrFWJN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\OTWM2OD16LkO0NFUzKM7:TR?= MYHTRW5ITVJ?
SCC-15 M{fF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqxbGxKSzVyPUGwMlc4QDhizszN NFLhemZUSU6JRWK=
BB49-HNC MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlTWM2OD1zND6zN|M2KM7:TR?= NFvY[lBUSU6JRWK=
ES7 NEDTTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHlTWM2OD1zND63N|c6KM7:TR?= M3u1PHNCVkeHUh?=
LB2518-MEL Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXyNI5KSzVyPUG2MlYxQTRizszN M1uye3NCVkeHUh?=
NCI-H510A NWXmWYVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TRUGlEPTB;MUeuNlQ1OiEQvF2= MXzTRW5ITVJ?
TE-441-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTLd3NKSzVyPUG3MlI5QDZizszN NXHnd4hYW0GQR1XS
HH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nNbmlEPTB;MUeuN|k6QSEQvF2= NYW4W5NOW0GQR1XS
LC4-1 NHnYR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS4TWM2OD1zOD6wOlUzKM7:TR?= MUnTRW5ITVJ?
KARPAS-45 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjMTXdKSzVyPUG4MlE5PDhizszN NWXC[3ByW0GQR1XS
LB1047-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDsNHN5UUN3ME2xPE41PDV{IN88US=> NUHpUIdDW0GQR1XS
NKM-1 NH:zS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH6wdo1KSzVyPUG5MlM2PTJizszN MWHTRW5ITVJ?
SCLC-21H M4TIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[zXI5GUUN3ME2yNE4yOjR4IN88US=> NV;QbYNsW0GQR1XS
RS4-11 M2HzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJyLkOzNFgh|ryP M{Ljb3NCVkeHUh?=
ALL-PO M2fjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;BfpliUUN3ME2yNE45OTR7IN88US=> M1q2PXNCVkeHUh?=
GDM-1 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zpbmlEPTB;MkKuOVk1PSEQvF2= MULTRW5ITVJ?
DMS-79 NVPWfWU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TqdGlEPTB;MkSuOFk{PCEQvF2= MlG5V2FPT0WU
MPP-89 NITmS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHyTWM2OD1{NT62PFc1KM7:TR?= MoXzV2FPT0WU
NB10 M2DPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHFemZKSzVyPUK2MlQ3QTlizszN NYXEbnAyW0GQR1XS
LS-513 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3IbXY4UUN3ME2yOk45QDR5IN88US=> MnXDV2FPT0WU
L-540 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4npb2lEPTB;Mk[uPVE1OyEQvF2= NVPyTnlCW0GQR1XS
ES1 NFrVUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjuTWM2OD1{Nz61NlEh|ryP NXz6XGZFW0GQR1XS
NTERA-S-cl-D1 NVrGTHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHNZYtrUUN3ME2zNE42ODl|IN88US=> M1LwW3NCVkeHUh?=
EW-1 NX6yWIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe1SpJKSzVyPUOyMlk1PTRizszN MU\TRW5ITVJ?
Calu-6 M3yzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmxXmloUUN3ME2zN{4yQDV3IN88US=> MkXqV2FPT0WU
CTV-1 NGXETmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT5Zm05UUN3ME2zN{46Pzh7IN88US=> MmHhV2FPT0WU
YT NW\kO21XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\iclBKSzVyPUO4MlUzODlizszN MkXBV2FPT0WU
TE-6 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGxepFKSzVyPUSxMlI4QThizszN M3[4NHNCVkeHUh?=
HT-144 NYXDWHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRzLkW0PFYh|ryP MVfTRW5ITVJ?
EW-13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH1TWM2OD12Mj6yO|kyKM7:TR?= M2jvSHNCVkeHUh?=
KALS-1 M3;3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjL[5R5UUN3ME20N{4yOzJ7IN88US=> MXXTRW5ITVJ?
MOLT-16 NUD6eXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Pk[mlEPTB;NEWuNFc2OiEQvF2= NYr0PZprW0GQR1XS
D-336MG M{f5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR3Lkm1PVkh|ryP MYjTRW5ITVJ?
TE-11 M4XFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rhemlEPTB;NE[uOlU{KM7:TR?= NFzUZldUSU6JRWK=
EB2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfpTWM2OD12Nj62PVkh|ryP NHHmdodUSU6JRWK=
SK-N-DZ NInWS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\POlZEUUN3ME20PE4xQTZzIN88US=> MmLmV2FPT0WU
SW684 NXnQdYtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3wTWM2OD12OD6yOlk2KM7:TR?= NHHmTFdUSU6JRWK=
EW-18 NXnjS3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTR6LkSzPVUh|ryP MoXBV2FPT0WU
RL95-2 M1KyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVyLkC3NUDPxE1? NY\HR3B1W0GQR1XS
CHP-126 M{DlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPDbpdKSzVyPUWwMlg6ODVizszN Ml\HV2FPT0WU
NCI-H1395 M{Li[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qyZWlEPTB;NUGuO|g{PSEQvF2= M2fYOHNCVkeHUh?=
TE-15 M4O2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn73TWM2OD13Mj6yOVU3KM7:TR?= MXnTRW5ITVJ?
ES4 NUDvdlVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLTbJRKSzVyPUWyMlk4PzVizszN M3ezdHNCVkeHUh?=
TE-1 M{HSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi4TWM2OD13Mz65OFU2KM7:TR?= NV3vOZBZW0GQR1XS
SIMA NVzXSXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTV5LkOzNVEh|ryP MXvTRW5ITVJ?
LB647-SCLC M2HnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn73TWM2OD14ND6xNVg5KM7:TR?= MkK2V2FPT0WU
KY821 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZ2LkK1OVIh|ryP NED1T25USU6JRWK=
LC-2-ad M3jzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr3VWFKSzVyPU[1Mlc3ODFizszN MlrZV2FPT0WU
KP-N-RT-BM-1 NUfWO5NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LLXGlEPTB;Nk[uOlM3PiEQvF2= MY\TRW5ITVJ?
SW872 NFnuUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELzV5VKSzVyPU[3MlQ{QDJizszN M3jTR3NCVkeHUh?=
ES5 NEPpVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLJfmZtUUN3ME22O{43QTZ6IN88US=> M4\DdHNCVkeHUh?=
SK-NEP-1 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XKVGlEPTB;NkiuN|gxOyEQvF2= MYrTRW5ITVJ?
RPMI-6666 NU\mWGlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXSTWM2OD15MT6wN|Ih|ryP NHvxWGlUSU6JRWK=
UACC-812 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLSTWM2OD15MT6xOlA6KM7:TR?= NVWyR492W0GQR1XS
COLO-829 NY\SVGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPIW3BKSzVyPUeyMlY6QDdizszN MYfTRW5ITVJ?
KP-N-YS NEjnWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLOZ3FXUUN3ME23Nk44OTN7IN88US=> NE\zRYNUSU6JRWK=
GI-1 NVvyeWRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTd|LkK4Olgh|ryP MXXTRW5ITVJ?
ETK-1 NF3jSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTd|LkS5N|Ih|ryP M4\SfXNCVkeHUh?=
LXF-289 NFrTdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7SU5NKSzVyPUezMlczQSEQvF2= M2fnOnNCVkeHUh?=
CAS-1 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zLT2lEPTB;N{OuPFg2PyEQvF2= M4DxTXNCVkeHUh?=
EW-22 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfuXWNKSzVyPUe0MlcyOTVizszN M2TGfXNCVkeHUh?=
NCI-H2196 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLtS2JVUUN3ME23OU43Ozd7IN88US=> MVnTRW5ITVJ?
EoL-1-cell MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rGS2lEPTB;OEGuOlk3OyEQvF2= M3rI[XNCVkeHUh?=
D-247MG NG\N[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPqTnh2UUN3ME24Nk4xOjR6IN88US=> NXPpXXh4W0GQR1XS
Becker NVvwTYFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljsTWM2OD16Mj6zOFgyKM7:TR?= NVfMZ25VW0GQR1XS
IST-MEL1 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\qbGRKSzVyPUiyMlM1QDJizszN NWHVeGV4W0GQR1XS
MDA-MB-134-VI NGHaXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[x[HY1UUN3ME24Nk42QTl4IN88US=> NXTRVZl4W0GQR1XS
NCI-H1092 MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\SfmVKSzVyPUi0MlAyQTdizszN MWrTRW5ITVJ?
KINGS-1 NUjHV|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz4eZFKSzVyPUi2MlE3OThizszN MmrIV2FPT0WU
HCC2218 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y3R2lEPTB;OE[uO|kyOyEQvF2= M1WyVHNCVkeHUh?=
GI-ME-N NIjXclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLzdG1uUUN3ME24O{44Pjl7IN88US=> MnLxV2FPT0WU
AM-38 M1PVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTh6LkO5OVMh|ryP Mn3lV2FPT0WU
KNS-42 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e0VmlEPTB;OEmuNVAyQCEQvF2= NHW5[4tUSU6JRWK=
C8166 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKUmlEPTB;OEmuOlEzPSEQvF2= MkTaV2FPT0WU
Ramos-2G6-4C10 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fDd2lEPTB;OEmuPFcyQSEQvF2= M2jjOHNCVkeHUh?=
CTB-1 M3;D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTlyLk[zOVch|ryP NWfJPHoxW0GQR1XS
HCE-4 NU\GZ2pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfBVI9KSzVyPUmxMlE{OzZizszN M1voZ3NCVkeHUh?=
NCI-H526 NV7nbFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLITWM2OD17Mj60NVA{KM7:TR?= NV;lR|VHW0GQR1XS
ECC4 NYPBZYl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknXTWM2OD17ND6yOVU2KM7:TR?= NFjDW5hUSU6JRWK=
NCCIT MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTl3LkOyPVIh|ryP MkL1V2FPT0WU
MZ7-mel NGLVO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXiVIFYUUN3ME25OU46ODRizszN NEDNRYhUSU6JRWK=
COLO-684 M2G5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P4d2lEPTB;OU[uNlM5PSEQvF2= MWDTRW5ITVJ?
SU-DHL-1 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;RSVlqUUN3ME25Ok46QDR{IN88US=> Mof6V2FPT0WU
SF126 NX\Te|RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3SGpKSzVyPUm3MlUzOTdizszN NETrS3pUSU6JRWK=
NMC-G1 NGTJfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS3RmY1UUN3ME25PE41PTV2IN88US=> NVjq[3U5W0GQR1XS
NB14 M1fXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LIZWlEPTB;OUiuPVIxQCEQvF2= MXvTRW5ITVJ?
VA-ES-BJ NFK0TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HKRmlEPTB;OUmuOFA2PiEQvF2= MYHTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-STAT5 / STAT5 ; 

PubMed: 18981115     


For phospho-STAT3 and Phospho-STAT5 detection, cells were then activated for 6 hrs with anti-CD3 and anti-CD28 Ab. Equivalent amounts of protein from cell lysates were separated by SDS-PAGE and western blot analysis was then performed using anti-phospho STAT3, anti-STAT3, anti-phospho STAT5 or anti-STAT5 Abs.

p-ZAP70 / ZAP70 / p-LAT / LAT ; 

PubMed: 18981115     


For the analysis of imatinib interference with early TCR signaling events, cells were activated for 5 min with anti-CD3 and anti-CD28 Abs and blots were probed with anti-phospho ZAP70, anti-ZAP70, anti-phospho LAT or anti-LAT antibodies. Untreated, non-activated cells were used as controls (NA).

p-STAT3 / STAT3 / p-STAT5 / STAT5 ; 

PubMed: 18981115     


For phospho-STAT3 and Phospho-STAT5 detection, cells were then activated for 6 hrs with anti-CD3 and anti-CD28 Ab. Equivalent amounts of protein from cell lysates were separated by SDS-PAGE and western blot analysis was then performed using anti-phospho STAT3, anti-STAT3, anti-phospho STAT5 or anti-STAT5 Abs.

p-ZAP70 / ZAP70 / p-LAT / LAT ; 

PubMed: 18981115     


For the analysis of imatinib interference with early TCR signaling events, cells were activated for 5 min with anti-CD3 and anti-CD28 Abs and blots were probed with anti-phospho ZAP70, anti-ZAP70, anti-phospho LAT or anti-LAT antibodies. Untreated, non-activated cells were used as controls (NA).

18981115
Immunofluorescence
RelB; 

PubMed: 20371728     


Nuclear proteins were extracted from the untreated and treated cells and nuclear levels of RelA and RelB were confirmed by immunocytochemistry 

Cortactin / F-actin ; 

PubMed: 20937825     


NIH3T3-SrcY527F cells were treated with DMSO or with 10 μm STI571 for 16 h, fixed and co-stained for cortactin (red, left panels) and F-actin (green, middle panels). Merged fields (right panels) demonstrate co-localization between cortactin and F-actin at invadopodia.

RelB; 

PubMed: 20371728     


Nuclear proteins were extracted from the untreated and treated cells and nuclear levels of RelA and RelB were confirmed by immunocytochemistry.

Cortactin / F-actin ; 

PubMed: 20937825     


NIH3T3-SrcY527F cells were treated with DMSO or with 10 μm STI571 for 16 h, fixed and co-stained for cortactin (red, left panels) and F-actin (green, middle panels). Merged fields (right panels) demonstrate co-localization between cortactin and F-actin at invadopodia.

20371728 20937825
Growth inhibition assay
Cell viability ; 

PubMed: 28435223     


(C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone. Abbreviations: IM, imatinib; SD, standard deviation.

28435223
In vivo

Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]

Protocol

Kinase Assay:

[1]

- Collapse

PDGF receptor kinase activity:

PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
Cell Research:

[3]

- Collapse
  • Cell lines: BON-1 cells and NCI-H727 cells
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (66.85 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 493.6
Formula

C29H31N7O

CAS No. 152459-95-5
Storage powder
in solvent
Synonyms Gleevec, Glivec, CGP057148B
Smiles CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03891901 Recruiting Drug: Imatinib|Drug: Isoniazid|Drug: Rifabutin Tuberculosis National Institute of Allergy and Infectious Diseases (NIAID) November 30 2020 Phase 2
NCT04326933 Not yet recruiting Drug: Tyrosine kinase Inhibitors (Imatinib & Nilotinib) Patients Diagnosed as Chronic Meyloid Leukemia Assiut University October 20 2020 --
NCT04357613 Not yet recruiting Drug: Experimental drug SARS Virus Versailles Hospital September 1 2020 Phase 2
NCT04422678 Not yet recruiting Drug: Imatinib Mesylate|Drug: Standard of Care COVID-19 Alexandria University|Science Technology & Innovation Funding Authority (STIFA) Egypt June 2020 Phase 3
NCT04097093 Withdrawn Other: No intervention GIST European Organisation for Research and Treatment of Cancer - EORTC June 1 2020 --
NCT03997903 Not yet recruiting Drug: Imatinib Mesylate Sickle Cell Disease Indiana University|Purdue University|Children''s Hospital Medical Center Cincinnati February 26 2020 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please advise whether it is a clear solution for compound dissolved in vehicle 2% DMSO+30% PEG 300+2% Tween 80+ddH2O?

  • Answer:

    For S2475 Imatinib (STI571), it is soluble in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 2mg/ml. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm it in water bath at 45-50C. Then add PEG and Tween. After they mixed well, dilute with water.

  • Question 2:

    What is the difference between S2475 (Imatinib) and S1026 (Imatinib Mesylate)? Are they water soluble?

  • Answer:

    S2475 is free base of Imatinib while S1026 is a solt form of Imatinib. They have exactly the same biological activity but different solubility. S1026 can be dissolved in water, but S2475 is not soluble in water. S2475 can be dissolved in DMSO at up to 3mg/ml.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Imatinib (STI571) | Imatinib (STI571) supplier | purchase Imatinib (STI571) | Imatinib (STI571) cost | Imatinib (STI571) manufacturer | order Imatinib (STI571) | Imatinib (STI571) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID